SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales surged to Rs. 49328.80 millions, up 34.58% for the June 2022 quarter as against Rs. 36652.90 millions during the corresponding quarter previous year.The Total Profit for the quarter ended June 2022 of Rs. 10118.00 millions grew from Rs.-1382.80 millionsThe company reported a good operating profit of 14986.50 millions compared to 4550.30 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 49328.80 36652.90 34.58 49328.80 36652.90 34.58 155859.80 141160.50 10.41
Other Income 1762.10 2116.90 -16.76 1762.10 2116.90 -16.76 11968.80 1920.70 523.15
PBIDT 14986.50 4550.30 229.35 14986.50 4550.30 229.35 38654.40 24490.80 57.83
Interest 870.70 1074.60 -18.97 870.70 1074.60 -18.97 3881.00 2675.20 45.07
PBDT 14115.80 1820.00 675.59 14115.80 1820.00 675.59 16568.10 20920.00 -20.80
Depreciation 3745.00 3069.30 22.01 3745.00 3069.30 22.01 13499.50 12364.30 9.18
PBT 10370.80 -1249.30 -930.13 10370.80 -1249.30 -930.13 3068.60 8555.70 -64.13
TAX 252.80 133.50 89.36 252.80 133.50 89.36 4068.50 131.70 2989.22
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 10118.00 -1382.80 -831.70 10118.00 -1382.80 -831.70 -999.90 8424.00 -111.87
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 30.38 12.41 144.72 30.38 12.41 144.72 24.80 17.35 42.95

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×